Rabies PEP: KEDRAB™ human rabies immune globulin receives FDA approval

Fort Lee, New Jersey based company, Kedrion Biopharma and Israeli company, Kamada Ltd. announced that KEDRABa [rabies immune globulin (Human)] has received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course ["]

The post Rabies PEP: KEDRABa human rabies immune globulin receives FDA approval appeared first on Outbreak News Today.